Skip to content

Clinical trials

Completed Phase 2 Congenital Abnormalities trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Congenital Abnormalities Phase: Phase 2 Status: Completed Clear all

109 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20016
20027
20034
200410
20057
20069
200710
200811
20093
20106
20115
20122
20134
20142
20151
20171
20191
20211

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed109

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center20
National Cancer Institute (NCI)19
Case Comprehensive Cancer Center11
City of Hope Medical Center4
Memorial Sloan Kettering Cancer Center4
Roswell Park Cancer Institute3
SWOG Cancer Research Network3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
Alliance for Clinical Trials in Oncology2
Asan Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Congenital Abnormalities109
Leukemia, Myeloid, Acute88
Leukemia54
Precursor Cell Lymphoblastic Leukemia-Lymphoma46
Myeloproliferative Disorders43
Leukemia, Lymphocytic, Chronic, B-Cell41
Leukemia, Myeloid, Chronic-Phase39
Lymphoma, Follicular39
Leukemia, Myeloid, Accelerated Phase38
Lymphoma, Large B-Cell, Diffuse37

Trials

Showing 1 to 25 of 109. Each trial links to its page on Pharma Observatory.

9 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.